Apogee Therapeutics, Inc. (APGE) quarterly income statement — complete revenue, gross profit & net income history
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 408K | -400K | 400K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | -408K | 400K | -400K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | 82.36M | 78.46M | 70.88M | 73.17M | 63.1M | 75.88M | 58.69M | 44.12M | 38.18M | 37.16M | 24.3M | 18.89M | 12.66M | 14.1M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 21.55M | 20.08M | 17.1M | 17.14M | 16.57M | 15.65M | 12.97M | 10.92M | 9.46M | 8.2M | 7.24M | 4.94M | 4.2M | 1.89M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Research & Development | 60.82M | 58.44M | 54.18M | 55.7M | 46.39M | 60.23M | 45.71M | 33.21M | 28.72M | 28.95M | 17.07M | 13.95M | 8.46M | 12.21M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | -68K | -400K | 325K | 143K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -82.77M | -78.06M | -71.28M | -73.17M | -63.1M | -75.88M | -58.69M | -44.12M | -38.18M | -37.16M | -24.3M | -18.89M | -12.66M | -14.1M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | -31.18% | -2.87% | -21.46% | -65.82% | -65.25% | -104.23% | -141.46% | -133.64% | -201.64% | -163.53% | - | - | - | - |
| EBITDA | -82.36M | -77.65M | -70.88M | -72.77M | -62.89M | -75.81M | -58.64M | -44.09M | -38.15M | -31.73M | -20.84M | 0 | 0 | -14.01M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -30.97% | -2.43% | -20.87% | -65.05% | -64.84% | -138.87% | -181.37% | - | - | -126.57% | - | - | - | - |
| D&A (Non-Cash Add-back) | 408K | 406K | 400K | 399K | 207K | 76K | 48K | 36K | 29K | 0 | 0 | 18.89M | 12.66M | 0 |
| EBIT | -82.77M | -78.06M | -64.96M | -73.17M | -63.1M | -75.88M | -58.69M | -44.12M | -38.18M | -31.73M | -20.84M | -18.89M | -12.66M | -14.01M |
| Net Interest Income | 8.74M | -21.3M | 6.32M | 7.14M | 7.84M | 8.68M | 9.67M | 10.31M | 6.09M | 5.42M | 3.46M | 0 | 133K | 92K |
| Interest Income | 8.74M | -21.3M | 6.32M | 7.14M | 7.84M | 8.68M | 9.67M | 10.31M | 6.09M | 5.42M | 3.46M | 0 | 133K | 92K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 8.74M | 8.73M | 6.32M | 7.14M | 7.84M | 8.68M | 9.67M | 10.31M | 6.09M | 5.42M | 3.46M | 0 | 133K | 92K |
| Pretax Income | -74.03M | -69.33M | -64.96M | -66.02M | -55.26M | -67.2M | -49.02M | -33.82M | -32.09M | -31.73M | -20.84M | -18.89M | -12.53M | -14.01M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax | 79K | 62K | 61K | 72K | 83K | 18K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.11% | -0.09% | -0.09% | -0.11% | -0.15% | -0.03% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -74.11M | -69.39M | -65.02M | -66.1M | -55.34M | -67.22M | -49.02M | -33.82M | -32.09M | -31.73M | -20.84M | -18.89M | -12.53M | -14.01M |
| Net Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -33.92% | -3.23% | -32.65% | -95.46% | -72.43% | -111.81% | -135.21% | -79.06% | -156.24% | -126.57% | - | - | - | - |
| Net Income (Continuing) | -74.11M | -69.39M | -65.02M | -66.1M | -55.34M | -67.22M | -49.02M | -33.82M | -32.09M | -31.73M | -20.84M | -18.89M | -12.53M | -14.01M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -1.06 | -1.03 | -1.11 | -1.13 | -0.95 | -1.22 | -0.86 | -0.60 | -0.64 | -0.63 | -0.41 | -0.37 | -0.25 | -0.28 |
| EPS Growth % | -11.58% | 15.57% | -29.07% | -88.33% | -48.44% | -93.65% | -109.76% | -62.16% | -156% | -125% | - | - | - | - |
| EPS (Basic) | -1.06 | -1.03 | -1.11 | -1.13 | -0.95 | -1.22 | -0.86 | -0.60 | -0.64 | -0.63 | -0.41 | -0.37 | -0.25 | -0.28 |
| Diluted Shares Outstanding | 69.67M | 60.69M | 58.77M | 58.43M | 58.2M | 55.19M | 56.8M | 56.52M | 50.19M | 50.66M | 50.67M | 50.67M | 50.67M | 50.67M |
| Basic Shares Outstanding | 69.67M | 60.69M | 58.77M | 58.43M | 58.2M | 55.19M | 56.8M | 56.52M | 50.19M | 50.66M | 50.67M | 50.67M | 50.67M | 50.67M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - | - | - | - | - |